In this component of the U54 program, promising drug candidates identified in the zebrafish screens described in Project 1 and advanced through in vivo structure activity relationship and medicinal chemistry studies in Project 2 will be tested in progressive translational animal efficacy studies using well-established mouse and rabbit models of cyanide poisoning. We anticipate that Project 2 will yield 4-5 highly promising optimized compounds each year. These candidates will then be tested in mice for in vivo efficacy and for safety in range finding studies. Efficacy will be tested in a well-validated cyanide gas inhalational model. We expect that of the 4-5 drugs tested each year, 2-4 will show promise in mice in terms of safety and efficacy, which will then progress to extensively monitored rabbit efficacy studies to determine physiologic effects, and rate of recovery in addition to survival outcomes. The drugs will be administered by intramuscular injection in both the mice and rabbits, since the CounterACT program is primarily interested in finding a cyanide antidote that could be given rapidly in the field. In addition, candidate drugs that progress to the rabbit model will also be assessed for efficacy via inhalation, since inhaled drugs are rapidly absorbed and this is an effective method to administer drugs to a large number of people. We anticipate that on average one drug per year will make it through the mouse and rabbit studies and be ready for formal toxicological and pharmacokinetic studies. The studies in this project require close collaboration with Project 2 and the Metabolomics Core, but we will also interact with Project 1 to explore mechanisms of drug toxicity during the development phase and to validate markers for specific populations vulnerable to cyanide toxicity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS079201-03
Application #
8730726
Study Section
Special Emphasis Panel (ZRG1-MDCN-J)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
3
Fiscal Year
2014
Total Cost
$482,551
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Sips, Patrick Y; Shi, Xu; Musso, Gabriel et al. (2018) Identification of specific metabolic pathways as druggable targets regulating the sensitivity to cyanide poisoning. PLoS One 13:e0193889
Nath, Anjali K; Shi, Xu; Harrison, Devin L et al. (2017) Cisplatin Analogs Confer Protection against Cyanide Poisoning. Cell Chem Biol 24:565-575.e4
MacRae, Calum A; Boss, Gerry; Brenner, Matthew et al. (2016) A countermeasure development pipeline. Ann N Y Acad Sci 1378:58-67
MacRae, Calum A; Peterson, Randall T (2015) Zebrafish as tools for drug discovery. Nat Rev Drug Discov 14:721-31
Palchaudhuri, Rahul; Lambrecht, Michael J; Botham, Rachel C et al. (2015) A Small Molecule that Induces Intrinsic Pathway Apoptosis with Unparalleled Speed. Cell Rep 13:2027-36
MacRae, Calum A (2015) A new phenotypic lexicon for accelerated translation: rise of the machines. Circulation 131:234-6
Burns, Andrew R; Luciani, Genna M; Musso, Gabriel et al. (2015) Caenorhabditis elegans is a useful model for anthelmintic discovery. Nat Commun 6:7485
Jackson, Randy; Oda, Robert P; Bhandari, Raj K et al. (2014) Development of a fluorescence-based sensor for rapid diagnosis of cyanide exposure. Anal Chem 86:1845-52
Musso, Gabriel; Tasan, Murat; Mosimann, Christian et al. (2014) Novel cardiovascular gene functions revealed via systematic phenotype prediction in zebrafish. Development 141:224-35
Lee, Jangwoen; Kim, Jae G; Mahon, Sari B et al. (2014) Noninvasive optical cytochrome c oxidase redox state measurements using diffuse optical spectroscopy. J Biomed Opt 19:055001

Showing the most recent 10 out of 16 publications